ERBB2 and breast cancer: This research aims to provide a robust evidence base for the clinical application of HLX02 and investigate the potential of combination therapy in preclinical models, offering insights that could inform and refine treatment strategies for HER2-positive BC, especially for patients with HR-positive disease.